Consejo Nacional de Salud

68 Micallef I N M, Kahl B S, Maurer MJ, Dogan
A, Ansell S M, Colgan J P, Geyer S, Inwards D
J, White W L, Habermann T M, A Pilot Study of
Epratuzumab and Rituximab in Combination With
Cyclophosphamide, Doxorubicin, Vincristine, and
Prednisone Chemotherapy in Patients With Previously
Untreated, Diffuse Large B-Cell Lymphoma,
CANCER December 15, 2006 / Volume 107 /
Number 12, 2828-32
69 Dann E J, Bar-Shalom R, Tamir A, Haim N, Ben-
Shachar M, Avivi I, Zuckerman T, Kirschbaum M,
Goor O, Libster D, Rowe J M, Epelbaum R, Riskadapted
BEACOPP regimen can reduce the cumulative
dose of chemotherapy for standard and
high-risk Hodgkin lymphoma with no impairment
of outcome, BLOOD, 1 February 2007 _ Volume
109, Number 3 From Www.Bloodjournal.Org By
On November 19, 2008.
70 Bramwell V, Anderson D, Charette M, Sarcoma
Disease Site Group . Doxorubicin-based chemotherapy
for the palliative treatment of adult
patients with locally advanced or metastatic soft
tissue sarcoma. Cochrane Database of Systematic
Reviews 2001, Issue 4. Art. No.: CD003293. DOI:
10.1002/14651858.CD003293.
71 Sarcoma Meta-analysis Collaboration (SMAC)*
(see Acknowledgements Section for list of authors
in SMAC). Adjuvant chemotherapy for localised
resectable soft tissue sarcoma in adults. Cochrane
Database of Systematic Reviews 2000, Issue 4.
Art. No.: CD001419. DOI: 10.1002/14651858.
CD001419.
72 van Dalen EC, Michiels EMC, Caron HN, Kremer
LCM. Different anthracycline derivates for reducing
cardiotoxicity in cancer patients. Cochrane
Database of Systematic Reviews 2006, Issue 4.
Art. No.: CD005006. DOI: 10.1002/14651858.
CD005006.pub2.
73 Tibaldi C, Prochilo T, Russo F, Pennucci MC, Del
Freo A, Innocenti F, Fabbri A, Falcone A, Conte PF,
Baldini E, Epirubicin/paclitaxel/etoposide in extensive-stage
small-cell lung cancer: a phase I–II study,
British Journal of Cancer (2006) 94, 1263 – 1266
74 van Dalen EC, Michiels EMC, Caron HN, Kremer
LCM. Different anthracycline derivates for reducing
cardiotoxicity in cancer patients. Cochrane
Database of Systematic Reviews 2006, Issue 4.
Art. No.: CD005006. DOI: 10.1002/14651858.
CD005006.pub2.
75 Wiernik PH; Banks PL; Case DC Jr; Arlin ZA; and
others Cytarabine plus idarubicin or daunorubicin
as induction and consolidation therapy for previously
untreated adult patients with acute myeloid
leukemia. Blood 1992 Jan 15; 79(2):313-9
76 Vogler WR; Velez-Garcia E; Weiner RS; Flaum
MA; and others A phase III trial comparing idarubicin
and daunorubicin in combination with cytarabine
in acute myelogenous leukemia: a Southeastern
Cancer Study Group Study. J Clin Oncol 1992
Jul;10(7):1103-11
77 Shelley M, Harrison C, Coles B, Stafforth J, Wilt T,
Mason M. Chemotherapy for hormone-refractory
prostate cancer. Cochrane Database of Systematic
Reviews 2006, Issue 4. Art. No.: CD005247.
DOI: 10.1002/14651858.CD005247.pub2.
78 Shelley M, Harrison C, Coles B, Stafforth J, Wilt T,
Mason M. Chemotherapy for hormone-refractory
prostate cancer. Cochrane Database of Systematic
Reviews 2006, Issue 4. Art. No.: CD005247.
DOI: 10.1002/14651858.CD005247.pub2.
79 Martinelli Boneschi F, Rovaris M, Capra R, Comi
G. Mitoxantrone for multiple sclerosis. Cochrane
Database of Systematic Reviews 2005, Issue 4.
Art. No.: CD002127. DOI: 10.1002/14651858.
CD002127.pub2.
GRUPO L | Agentes antineoplásicos e inmunomoduladores
395
L